|
|||||
|
|
HeberFERON,a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment |
|
| Authors: | Iraldo Bello-Rivero Yanelda Garcia-Vega Yaquelin Duncan-Roberts Dania Vazquez-Blomquistc Hector Santana-Milian Vladimir Besada-Perez Margarita Rios-Cabrera |
| Affiliation: | 1. Clinical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba;2. Clinical Trial Department, Center of Molecular Immunology, Havana, Cuba;3. Genomic Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba;4. Formulation Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba;5. Proteomic Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba;6. Department of Clinical Trial, Hospital Arnaldo Milian Castro, Villa Clara, Cuba |
| Abstract: | The rational combination of recombinant IFN-α2b and IFN-γ resulted in a new formulation of interferons (HeberFERON) with improved pharmacodynamics. In basal cell carcinomas HeberFERON produces a more rapid antitumor effect and results in a larger number of complete responses. In patients with glioblastoma multiforme, the administration of HeberFERON after surgery and radiotherapy results in an estimated overall survival of 19 months. Patients with stage III or IV renal cell carcinoma also appear to benefit from the intravenous administration of HeberFERON, with prolongation of survival and good quality of live. HeberFERON offers a promising alternative formulation of interferons for the treatment of cancer with a very favorable safety profile. |
| Keywords: | HeberFERON skin cancer renal carcinoma brain tumor |
| 本文献已被 ScienceDirect 等数据库收录！ | |